Concepedia

Hilary Glen

HG

Statistics

Publications

24

Citations

2K

H-Index

17

Active since

2005

Affiliations

Beatson West of Scotland Cancer Centre(Current)

The Christie NHS Foundation Trust

Royal Marsden NHS Foundation Trust

St James's University Hospital

Eisai (United States)

Hilary Glen is an author at Beatson West of Scotland Cancer Centre specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2005–2024

24

Publications

24

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

, , +14

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

David S. Boss, Hilary Glen, Jos H. Beijnen et al. · British Journal of Cancer · 2012 · 185 citations · Full text

, , +14

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

, , +11

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

, , +17

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

Hilary Glen, Susan Mason, Hitesh Patel et al. · BMC Cancer · 2011 · 88 citations · Full text

, , +17

1–5 of 24